Aldevron Breakthrough Blog
Presentation: Innovation to Commercialization
February 19, 2025 by Max Sellman
CRISPR Medicine Manufacturing Solutions for the Next Decade
With FDA approval of the first CRISPR-based therapeutic in late 2023, and many more programs advancing through trials, demand for genetic medicines are poised to grow substantially in the coming years.
Max Sellman, Senior Product Manager for Gene Editing at Aldevron, has had a front-row seat in seeing how CRISPR therapeutics have advanced over the last decade, and how tremendous progress has been made in the field to develop cures for diseases and improve patient outlooks.
But beyond where we’ve been, in a presentation at the Genome Editing Therapeutics Summit (formerly CRISPR 2.0), Sellman is looking to the future of CRISPR, and how Aldevron is preparing to support these types of clinical programs as they grow and advance onto the market.
View From Innovation to Commercialization: CRISPR Medicine Manufacturing Solutions for the Next Decade
- Have questions on this topic? Contact Us
- Learn more about our CRISPR offerings
- Have an idea for a topic? Let us know!
Max Sellman is Senior Product Manager, Gene Editing, at Aldevron focusing on gene editing protein products and custom services since 2017. Prior to Aldevron, Max was a Business Development and Alliance Management Lead for BioTechnique, a GMP fill/finish CMO. Max holds a bachelor’s degree from the University of Wisconsin in Genetics and Life Sciences Communication.